Marriott's November Print Arrives With the Stock Above Analyst Consensus
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
MAR reports third-quarter results on November 2 with its shares at $399.30, up 10% over the past month and now trading above the Street's mean price target of $387.77.
That gap between price and consensus is the central tension in the setup. Morgan Stanley raised its target to $403 last week, maintaining Overweight, while JP Morgan lifted to $406 but held at Neutral, a posture that signals comfort with the fundamentals but not with paying more for them. Evercore ISI moved to $420 and Wells Fargo to $426, both positive on the name. Barclays, by contrast, raised only to $363, well below where the stock trades. The pattern is one of analysts acknowledging the momentum without leading it: five target increases in two weeks, yet the median number still sits below the current price. The forward earnings multiple has expanded roughly 10% over the past month to around 31 times, leaving little room for a guidance miss.
The bear case rests on cyclical exposure. North America accounts for 61% of rooms, and the asset-light, fee-dependent model ties results directly to third-party hotel occupancy and room rates. Any softening in business or leisure travel would flow through quickly to managed and franchise fees, with limited balance-sheet buffers given the company's structurally negative book value. The bull case is the mirror of that model: fee generation from 1.8 million rooms across roughly 30 brands is highly scalable, the pipeline of around 618,000 rooms provides a long runway for net unit growth, and the company has guided to return more than $4.4 billion to shareholders in 2026. With Q2 adjusted EPS guided at $2.99 to $3.06 and gross fee growth of 10% to 11%, the question is whether Q3 sustained that trajectory.
Options positioning offers a mild note of caution. The put/call ratio has edged up to 0.94, modestly above its 20-day average of 0.93, though still far from the 52-week high of 1.02 hit earlier in October. The z-score of 0.30 suggests the move is not statistically meaningful; this is not a market bracing hard for a downside shock. Short interest carries even less signal: at 2.5% of the free float and falling steadily over the past month, short positions have been reduced, not built. Borrow availability is extremely loose, with more than 4,900% availability relative to shares currently lent out, meaning the lending market is placing no friction on anyone wishing to short the stock.
One ownership note worth flagging: J.W. Marriott, Jr. filed a Schedule 13D in January disclosing an 11.4% stake of roughly 30.7 million shares. The 13D classification indicates activist-level disclosure, though the Marriott family's long-standing involvement in the company makes the designation more structural than confrontational. As a standard caveat, 13D/G positions are disclosed around the 5% threshold and may not reflect current holdings precisely. Separately, the insider record shows three members of the Marriott family each sold 3,500 shares at around $352 in late September, a combined open-market disposal of roughly $3.7 million in net value over the past 90 days, on no declared 10b5-1 plan.
The November 2 print will test whether fee growth held up through the summer travel period and whether net unit growth is progressing fast enough to justify a price-to-earnings ratio that has expanded ahead of the company's own analyst consensus.
Stocks in this article
See the live data behind this article on ORTEX.
Open MAR on ORTEX →How this article was generated
- Generated
- 31 Oct 2026, 04:31
- Data as of
- 31 Oct 2026, 04:04
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt DataPrevious Mi Articles
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.